Skip to main content

Janumet FDA Approval History

FDA Approved: Yes (First approved March 30, 2007)
Brand name: Janumet
Generic name: metformin and sitagliptin
Dosage form: Tablets
Company: Merck
Treatment for: Diabetes, Type 2

Janumet is a combination of the oral antihyperglycemic drugs sitagliptin and metformin indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus.

Development timeline for Janumet

DateArticle
Feb  2, 2012Approval FDA Approves Janumet XR (sitagliptin and metformin HCl extended-release) for Type 2 Diabetes, Offering the Powerful Efficacy of Janumet (sitagliptin/metformin HCl) Now Available with Once-Daily Convenience
Apr  2, 2007Approval FDA Approves Janumet for Type 2 Diabetes, Offering Powerful GlucoseControl of a DPP-4 Inhibitor and Metformin in a Single Tablet
Dec  1, 2006Merck Announces Janumet, the Trademark for its Investigational Combination Therapy of Sitagliptin Phosphate and Metformin for Type 2 Diabetes
Jul 31, 2006Merck Announces FDA Acceptance of NDA for MK-0431A

See also

Janumet (metformin and sitagliptin) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer